1. 263TiPATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer. (24th November 2019) Authors: Fujiwara, K; Chou, H-H; Kim, J-W; Tan, D S; Tamura, K; Katsumata, N; Harano, K; Hasegawa, K; Hume, S; Jones, E; Goble, S; Sullivan, L; Shih, D; Coleman, R L; McNeish, I; Monk, B; Kristeleit, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P158 Outcome of inflammatory bowel disease strictures. (16th January 2018) Authors: Schulberg, J; Wright, E; Holt, B; Sutherland, T; Hume, S; Hamilton, A; Ross, A; Kamm, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗